TransMedics Group Analyst Price Targets

Wall Street analyst price targets and consensus rating for TransMedics Group (TMDX).

Price Target Range — 13 Quarters

Analyst Consensus — 13 Analysts

10Buy

3Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$114Upside to Avg. PT+43.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Christopher Pasquale	Initiate	Overweight	$120
Sep 8, 2026	TD Cowen	Joshua Jennings	Maintained	Buy	$120
Aug 5, 2026	UBS	Patrick Wood	PT Cut	Neutral	$80→$77
Aug 5, 2026	Piper Sandler	Matt O'Brien	PT Cut	Overweight	$120→$100
Aug 3, 2026	Needham	Mike Matson	PT Cut	Buy	$142→$106
Jul 28, 2026	UBS	—	Initiate	Neutral	$80
Jul 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	Outperform	$100→$90
Jul 1, 2026	TD Cowen	Joshua Jennings	Maintained	Buy	$120
Jun 30, 2026	Canaccord Genuity	William Plovanic	Maintained	Buy	$124
Jun 18, 2026	Stifel	Tom Stephan	PT Raise	Hold	$75→$80
May 26, 2026	Stifel	Tom Stephan	PT Cut	Hold	$85→$75
May 6, 2026	Canaccord Genuity	William Plovanic	PT Cut	Buy	$152→$124
May 6, 2026	TD Cowen	Joshua Jennings	PT Cut	Buy	$190→$120
May 6, 2026	Stifel	Thomas Stephan	PT Cut	Hold	$130→$85
May 6, 2026	Piper Sandler	Matt O'Brien	PT Cut	Overweight	$160→$120
May 6, 2026	Needham	Mike Matson	PT Cut	Buy	$174→$142
Apr 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	Outperform	$170→$118
Mar 9, 2026	Stifel	Thomas Stephan	PT Raise	Hold	$115→$130
Feb 25, 2026	JP Morgan	Allen Gong	PT Raise	Neutral	$114→$149
Feb 25, 2026	Oppenheimer	Suraj Kalia	PT Raise	Outperform	$150→$175

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120

Barclays analyst Christopher Pasquale initiates coverage on TransMedics Group (NASDAQ:TMDX) with a Overweight rating and announces Price Target of $120.

Benzinga Newsdesk

PRO
TD Cowen Reiterates Buy on TransMedics Group, Maintains $120 Price Target

TD Cowen analyst Joshua Jennings reiterates TransMedics Group (NASDAQ:TMDX) with a Buy and maintains $120 price target.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on TransMedics Group, Lowers Price Target to $77

UBS analyst Patrick Wood maintains TransMedics Group (NASDAQ:TMDX) with a Neutral and lowers the price target from $80 to $77.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on TransMedics Group, Lowers Price Target to $100

Piper Sandler analyst Matt O'Brien reiterates TransMedics Group (NASDAQ:TMDX) with a Overweight and lowers the price target from $120 to $100.

Benzinga Newsdesk

PRO
Needham Maintains Buy on TransMedics Group, Lowers Price Target to $106

Needham analyst Mike Matson maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $142 to $106.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on TransMedics Group, Lowers Price Target to $90

Evercore ISI Group analyst Daniel Markowitz maintains TransMedics Group (NASDAQ:TMDX) with a Outperform and lowers the price target from $100 to $90.

Benzinga Newsdesk

TransMedics Group Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

TransMedics Group Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120

PRO
TD Cowen Reiterates Buy on TransMedics Group, Maintains $120 Price Target

PRO
UBS Maintains Neutral on TransMedics Group, Lowers Price Target to $77

PRO
Piper Sandler Reiterates Overweight on TransMedics Group, Lowers Price Target to $100

PRO
Needham Maintains Buy on TransMedics Group, Lowers Price Target to $106

PRO
Evercore ISI Group Maintains Outperform on TransMedics Group, Lowers Price Target to $90

People Also Watch

People Also Watch

TransMedics Group Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

TransMedics Group Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120

PROTD Cowen Reiterates Buy on TransMedics Group, Maintains $120 Price Target

PROUBS Maintains Neutral on TransMedics Group, Lowers Price Target to $77

PROPiper Sandler Reiterates Overweight on TransMedics Group, Lowers Price Target to $100

PRONeedham Maintains Buy on TransMedics Group, Lowers Price Target to $106

PROEvercore ISI Group Maintains Outperform on TransMedics Group, Lowers Price Target to $90

People Also Watch

People Also Watch

PRO
Barclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120

PRO
TD Cowen Reiterates Buy on TransMedics Group, Maintains $120 Price Target

PRO
UBS Maintains Neutral on TransMedics Group, Lowers Price Target to $77

PRO
Piper Sandler Reiterates Overweight on TransMedics Group, Lowers Price Target to $100

PRO
Needham Maintains Buy on TransMedics Group, Lowers Price Target to $106

PRO
Evercore ISI Group Maintains Outperform on TransMedics Group, Lowers Price Target to $90